ACADIA to Host Conference Call and Webcast on Tuesday, August 5,2014, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Jul. 29, 2014—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in neurological and related centralnervous system disorders, today announced that it will report itsunaudited financial results for the second quarter ended June 30, 2014on Tuesday, August 5, 2014, after the U.S. financial markets close.ACADIA's management will host a conference call and webcast on Tuesday,August 5, 2014, at 5:00 p.m. Eastern Time to discuss ACADIA’s financialresults and development programs.
The conference call may be accessed by dialing 866-578-5771 forparticipants in the United States or Canada and 617-213-8055 forinternational callers (reference passcode 94851179). A telephone replayof the conference call may be accessed through August 19, 2014 bydialing 888-286-8010 for callers in the United States or Canada and617-801-6888 for international callers (reference passcode 56603137).The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.com,under the investors section and will be archived there until August 19,2014.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines that address unmet medicalneeds in neurological and related central nervous system disorders.ACADIA has a pipeline of product candidates led by pimavanserin, forwhich we have reported positive Phase III trial results in Parkinson’sdisease psychosis and which has the potential to be the first drugapproved in the United States for this disorder. We are currentlycompleting NDA-enabling clinical and manufacturing activities forpimavanserin and are planning to submit an NDA with the FDA near the endof 2014. Pimavanserin is also in Phase II development for Alzheimer’sdisease psychosis and has successfully completed a Phase II trial inschizophrenia. ACADIA also has clinical-stage programs for chronic painand glaucoma in collaboration with Allergan, Inc. and two preclinicalprograms directed at Parkinson’s disease and other neurologicaldisorders. All product candidates are small molecules that emanate frominternal discoveries. ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,including clinical trials; the benefits to be derived from ACADIA’sproduct candidates, in each case including pimavanserin; the potentialof pimavanserin to be the first drug approved in the United States forParkinson’s disease psychosis; and ACADIA’s plans to submit an NDA nearthe end of 2014. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2013as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, Executive VicePresident,
Chief Financial Officer and Chief Business Officer
LisaBarthelemy, Director of Investor Relations
(858) 558-2871